Nirmal Bang: Sun Pharma’s Specialty Portfolio Prescription Trends
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Sun Pharmaceutical Industries Ltd.’s effort around specialty portfolio ramp up is yielding favorable progress as prescription trends around the key products suggest growth on a QoQ basis.
Levulan which was significantly below pre Covid-19 levels has broadly normalized, but we need to monitor the impact of resurgence in Covid cases.
We are in fact seeing faint signals of an unfavorable impact of the second Covid wave as trends seems to suggest weakening prescription volumes across product categories in the last week of November.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.